Batch manufacture of high titer/titre GMP (U.S.A.) compliant lentiviral vector for FDA approval

See procurement documentation for all un-abridged description.

DEFINITIONS

FDA is the U.S Food and Drug Administration (FDA); the regulator for new clinical drugs

GMP means ‘Good Manufacturing Practice’; U.S.A.

IND is an “Investigational New Drug Application”; a request to the FDA to be permitted to

administer a new prototype drug on human patients for research purposes

Lentiviral vector (LVV) is a type of virus (retrovirus) that inserts its DNA into the cells of

the organism/person it infects.

Plasmid is a small DNA molecule which stores non-chromosomal DNA.

Must-have capabilities

• Able to produce a 30L harvest of unconcentrated LVV-containing supernatant following

transduction of 293T cells from a certified Master Cell Bank with genome and packaging

plasmids supplied by the University

• Able to concentrate this supernatant by a factor of approx. 100-200x to produce a

concentrated high titre LVV

• The supplier must have extensive prior experience of such manufacture and have

achieved numerous regulatory approvals for use of their LVV products in phase I/II clinical

trials. This is critical to ensure there is confidence that the supplier product will be

acceptable and well-received for regulatory approval.

o 10 years prior experience of manufacturing GMP-compliant LVV products

o Achieved minimum of 50 prior regulatory approvals (ideally FDA) of GMP-compliant

LVV products

• Supplied should follow all relevant legislation applicable to this engagement including in

their location/s of manufacture, and the State of California, USA

• The supplier should demonstrate a manufacturing process which is compliant with GMP

and that gives high confidence of their ability to deliver a high quality, compliant, product.

• For the purposes of greater transparency, collaboration and regulatory traceability and

accountability we require a direct relationship with the manufacturing entity/lead and

therefore bids proposed by an entity acting solely as a reseller/distributor will unfortunately

not be acceptable for this requirement. It is our expectation that the bidder undertakes the

manufacturing; however other functions like Quality Control may be undertaken by

subcontractors providing that the bidder takes full ultimate responsibility for delivery of the

contract.

• The supplier should demonstrate a reasonable and practicable solution for logistical

delivery of the product.

• For transparency we have a budget appetite of approximately USD560k for the delivery

of the initial services. We may review this estimate from time to time.

Desirable criteria

• It is desirable that the supplier can complete end to end delivery of initial requirement

(including manufacture, quality control and regulatory pack preparation), within 12 months

or faster from contract signature. Fast delivery times are desirable for the project.

• It is desirable that the supplier takes full accountability for the transport of the product

from the site of manufacture to UCLA.

Quality control (‘QC’);

This will require comprehensive GMP compliance QC to be performed:

Supplier will be required to provide details of the GMP-compliant manufacturing process

Intellectual property

For avoidance of doubt; the intellectual property (“IP”) the University provides during the

project in relation to the product specification will remain vested in the University and its

licensors and nothing in the awarded contract shall constitute granting a license, creating

a joint endeavour, creating joint IP, or otherwise constituting a license or transfer of IP to

the Supplier, that would entitle the Supplier to take any action utilising that IP beyond the

bounds of the Services which will be agreed between the University and Supplier

pursuant of this tender.